We offer a comprehensive suite of antibody generation platforms designed to provide high-affinity, internalizing antibodies ideal for drug conjugation. Our focus on developability, internalization, and conjugation-compatibility ensures you receive antibodies ready for downstream functionalization and therapeutic development.
Antibody Discovery
Efficient and scalable antibody production is foundational to ADC development. Whether you are screening multiple candidates or generating large-scale material for conjugation and preclinical evaluation, Aurigene offers flexible expression platforms tailored to your project timeline and stage. From rapid transient expression for early-stage ADCs to stable cell line development for consistency batches, our upstream capabilities are designed to ensure high-quality antibody supply optimized for downstream conjugation and analytical success.
Transient Expression
- Rapid antibody generation using HEK293 or CHO systems
- Ideal for early-stage ADC screening and quick turnaround
- Typical yields: 50–400 mg/L (HEK); up to 1 g/L (CHO)
- Antibodies purified via Protein A, ion exchange (if needed), and SEC
Get high-purity antibodies ready for conjugation in just 2–3 weeks.
Stable Cell Line Development
- Generation of CHO-based stable clones for long-term, scalable production
- Clone screening based on titer, growth profile, and product quality
- High-yield fed-batch process with optimization of expression vectors and media
Consistency, scalability, and control for large-scale ADC programs
Downstream Purification for Conjugation Readiness
- Platform purification using Protein A, SEC, HIC, and IEX
- Endotoxin control, buffer exchange, and low aggregation guaranteed
- Analytical QC: SDS-PAGE, SEC, endotoxin, intact mass, and reduced mass
Ensures conjugation-grade antibodies with full lot release documentation
Why Choose Aurigene for Antibody Production?
At Aurigene, our antibody production is tightly integrated with the downstream bioconjugation workflow ensuring that every batch is not just pure, but conjugation-ready. We offer flexible production formats, rapid timelines, and quality control designed specifically for the unique needs of ADC development. Whether your program needs 1 mg or 1 g, our agile team and modular facilities can scale with your project without compromising on quality or timelines.
We offer:
CHO and HEK-based systems for flexible, rapid expression
Conjugation-optimized production workflows from day one
Experienced upstream and purification scientists with ADC focus
Full characterization support: Mass, DAR, aggregation, and endotoxin
Seamless integration with conjugation, analysis, and in vitro teams
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Resources
FEBRUARY 25, 2025
Transforming Drug Discovery with Aurigene.AI
In the early 2000s, developing Sovaldi, a hepatitis C treatment, took over a decade and nearly $2 billion. Similarly, Zolgensma, a gene therapy for spinal muscular atrophy, required 15 years due to its complexity. However, the advent of artificial intelligence (AI) has revolutionized drug discovery. For example, in 2022, Pfizer's PAXLOVID, an oral COVID...
Read More
Advancement in personalized medicine and how the CRDMO industry is part of the solution
Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...
Read More
Cell Line Development
We enable development of stable and high yielding recombinant Mammalian and Microbial lines. ...
Read More
Familiarization, process optimization, and cGMP manufacturing and supply of 30.0 kg of a Bioactive Nucleotide (NAD Booster)
Background: A US-based biopharmaceutical company approached Aurigene Pharmaceutical Services for the familiarization, process development, and cGMP manufacturing and supply of 30.0 kg Nucleotide product (NAD booster) for phase-appropriate studies. The synthesis of the desired product involves three linear stages, which starts with reaction of a pentose...
Read More
Identification of Degradants of Thermal and Oxidation Stress Studies of Empagliflozin and Linagliptin Tablets by HPLC-PDA and LC-MS Instrumental Techniques
2022
Objective of the manuscript is to identify the degradants observed in the thermal and oxidation degradation sample of Empagliflozin and Linagliptin tablets by using LC-MS and HPLC-PDA instrumental techniques. Thermal and oxidation degradation samples were injected in HPLC-PDA and LC-MS instruments. Mass of the degradants were detected by LC-MS technique, ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Wang-OSO3H catalyzed green synthesis of bioactive isoindolo[2,1- a ]quinazoline-5,11–dione derivatives: An unexpected observation
2005
The sulphonic acid-functionalized Wang resin (Wang-OSO3H) was explored as a polymeric and recov- erable acidic catalyst for the synthesis of isoindolo[2,1- a ]quinazoline-5,11–dione derivatives under green conditions. Thus the Wang-OSO3H ...
Read More -
Polycyclic Aromatic Compounds: A Simple and Efficient [(n-Bu3Sn)2MO4]n Catalyzed Synthesis of Quinazolinones and Dihydroquinazolinones
2005
A novel unprecedented approach for the synthesis of various quinazolinones and dihydroquinazolinones has been using [(n-Bu3Sn)2MO4]n as a catalyst. The reaction has been screened ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market